Heraeus’ coil technology with dual-directional torque response
Heraeus Medical Components has developed a coil technology that the company says could disrupt the catheter-based treatment of complex coronary and peripheral artery diseases.
Heraeus’ three-layer TriFlex coil technology platform with dual-directional torque response was designed for numerous therapies. It resists compression, providing better pushability for improved access to hard-to-reach places, can cross complex lesions and delivers the flexibility needed to go through complex, tortuous anatomy. The company says the unique coil configuration can enable design teams to develop delivery systems with improved device deployment accuracy, and ultimately an improved experience for both the physician and the patient.
Heraeus (Saint Paul, Minn.) uses TriFlex in its own latest microcatheter to address critical clinical issues such as improved torque transmission for optimal vessel selection. The technology is used to treat cardiovascular disease, and chronic total occlusions (CTO) in coronary and peripheral vasculature such as critical limb ischemia (CLI), which frequently results in the amputation of lower limbs.
The coil’s precise torque response makes it a suitable component for inclusion in devices designed for other conditions that require precise therapy delivery to hard-to-reach parts of the body such as transcatheter aortic valve replacement (TAVR), mitral valve replacement (MVR) and repair, atrial septal defect (ASD) occlusion and left atrial appendage (LAA) occlusion.
The innovations could result in faster procedures, a reduction in failure rates, and a reduction in overall treatment costs, the company added.